Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zivo Bioscience, Inc. (OTC: ZIVO).

Full DD Report for ZIVO

You must become a subscriber to view this report.


Recent News from (OTC: ZIVO)

Food & Beverage/Consumer Packaged Goods Industry Veteran Joins ZIVO Bioscience, Inc. as VP - Global Operations
KEEGO HARBOR, MI / ACCESSWIRE / June 21, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from its proprietary algal strains, announces today that Ronald C. Costephens has joined the Com...
Source: ACCESSWIRE
Date: June, 21 2018 08:00
Zivo Bioscience, Inc. Reports Positive Results for Synthetic Therapeutic Candidates in a Pilot Experiment as Part of Bovine Mastitis Drug Discovery Program
KEEGO HARBOR, MI / ACCESSWIRE / June 13, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from its proprietary algal strains, announces today that it has received positive results from ...
Source: ACCESSWIRE
Date: June, 13 2018 07:45
Daily Insider Ratings Round Up 5/25/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: May, 26 2018 13:43
Zivo Bioscience, Inc. Announces Results For 90-Day Safety & Toxicology Study, Clearing the Way to Regulatory Compliance For Dried Algae Biomass Product
KEEGO HARBOR, MI / ACCESSWIRE / May 1, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that a final report for safety/toxicology tests pe...
Source: ACCESSWIRE
Date: May, 01 2018 12:45
Zivo Bioscience, Inc. Executes Letters of Intent with India-Based Algae Producers, Ships Algal Starter Inoculum to Growers in Taiwan
KEEGO HARBOR, MI / ACCESSWIRE / April 24, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today that Wellisen Nutraceuticals and Sanat Products...
Source: ACCESSWIRE
Date: April, 24 2018 13:10
ZIVO Bioscience, Inc. Welcomes New Vice-President of Research & Development
KEEGO HARBOR, MI / ACCESSWIRE / March 29, 2018 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today William P. Pfund has joined the Company as its ...
Source: ACCESSWIRE
Date: March, 29 2018 08:00
New Research Coverage Highlights ZIVO Bioscience and Nobility Homes - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of ZIVO Bioscience, Inc. ( OTCQB: ZIVO ) and Nobility Homes Inc. ( OTCQX: NOBH ), including recent technical analysis and consolidated fundamental information....
Source: ACCESSWIRE IA
Date: March, 08 2018 08:30
Largest Shareholder of ZIVO Bioscience, Inc. to extend maturity date of its Convertible Debt
KEEGO HARBOR, Mich., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today its largest shareholder, HEP Investment...
Source: GlobeNewswire
Date: February, 12 2018 18:09
ZIVO Bioscience and Tianjin Norland Biotech Execute Letter of Intent to Produce ZIVO Algae Strain in China for International and Domestic Markets
KEEGO HARBOR, Mich., Feb. 01, 2018 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO), a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today the execution of a letter of intent to...
Source: GlobeNewswire
Date: February, 01 2018 07:52
ZIVO Bioscience Subsidiary Wellmetris Selected to Present at Biotech Showcase During JPMorgan Healthcare Conference Jan 7-10 in San Francisco, CA
KEEGO HARBOR, Mich., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO), a biotech/agtech R&D company, announced today that its WellMetris subsidiary will be presenting at the Biotech Showcase at the Hilton San Francisco Union Square hotel on Wednesday, January 10 du...
Source: GlobeNewswire
Date: January, 08 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.13730.13350.13950.12143,042
2018-12-130.11550.1350750.1390.11136128,000
2018-12-120.12010.13930.13930.119961,950
2018-12-110.13880.13970.1430.115181,154
2018-12-100.1250.140.1430.11901423,028

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1484,466143,04259.0498Short
2018-12-13121,500128,00094.9219Short
2018-12-1251,40061,95082.9701Short
2018-12-1186,044181,15447.4977Short
2018-12-10256,929423,02860.7357Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZIVO.


About Zivo Bioscience, Inc. (OTC: ZIVO)

Logo for Zivo Bioscience, Inc. (OTC: ZIVO)

Zivo Bioscience, Inc. is a Michigan based biotech company engaged: in the investigation of the health benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as potential candidates for future medicinal and pharmaceutical applications in humans and animals, focused on autoimmune modulation and developing, manufacturing, marketing, and selling tests that the Company believes will allow people to optimize their health and identify future health risks.

 

Contact Information

 

 

Current Management

  • Andrew A Dahl / CEO
    • Mr. Dahl was appointed President / Chief Executive Officer on December , . Mr. Dahl is managing member and principal consultant at Great Northern amp Reserve Partners, a management consulting firm he founded in that provides marketing and business consulting services to biotech, biomedical and information technology companies. Previously, Mr. Dahl served as President of Dawber amp Company, formerly one of the oldest and largest independent marketing amp consulting firms in the Midwest, with an extensive Fortune client roster that included GM, Ford, AT amp T, Compuware and Xerox, among others. Dahl was employed by Dawber amp Company for nearly years until its partners dissolved the firm in . He attended the College for Creative Studies and Wayne State University. Mr. Dahl holds three US patents for interactive multimedia and is a named inventor in three recent biomedical patent applications.
  • Philip M. Rice II / CFO
    • Mr. Rice was appointed Chief Financial Officer in November, . In January, Mr. Rice was appointed to the Board of Directors. In , Mr. Rice founded Legacy Results, LLC now Legacy Results Inc. , a management consulting firm providing a wide range of consulting services, including strategic planning, business plan development, turnaround management, financial management, and mergers and acquisitions, and has served as its Managing Partner since that date. From December, through March, , Mr. Rice also served as Chairman of the Board of mix Solutions, Inc., a technology company providing secure internet transactions, including private data transactions. Mr. Rice practiced as a CPA and worked for Deloitte amp Touch LLP for thirteen years before founding Legacy Results.
  • Angela Chunovich / Manager, Controller
  • Philip M. Rice II / Chairman
    • Mr. Rice was appointed Chief Financial Officer in November, . In January, Mr. Rice was appointed to the Board of Directors. In , Mr. Rice founded Legacy Results, LLC now Legacy Results Inc. , a management consulting firm providing a wide range of consulting services, including strategic planning, business plan development, turnaround management, financial management, and mergers and acquisitions, and has served as its Managing Partner since that date. From December, through March, , Mr. Rice also served as Chairman of the Board of mix Solutions, Inc., a technology company providing secure internet transactions, including private data transactions. Mr. Rice practiced as a CPA and worked for Deloitte amp Touch LLP for thirteen years before founding Legacy Results.
  • Christopher Maggiore / Director
    • Mr. Maggiore was appointed in August, to serve as a director of the Company. Mr. Maggiore is a successful entrepreneur and has been involved in real estate development, building and management of businesses for over years. He currently owns and manages a portfolio of businesses and investments.
  • Nola E Masterson / Independent Director
    • Ms. Masterson was appointed in September to serve as a director of the Company. Since , she has been the chief executive officer of Science Futures, Inc., an investment and advisory firm. Ms. Masterson is currently Managing Member and General Partner of Science Futures LLC, I and II, which are venture capital funds invested in life science funds and companies. She is Chairman of the Board of Repros Therapeutics Inc. and serves on the audit committee, nominating committee and the compensation committee. Ms. Masterson was a biotechnology analyst on Wall Street, working with Drexel Burnham Lambert and Merrill Lynch, and is a cofounder of Sequenom, Inc., a genetic analysis company located in San Diego, California and Hamburg, Germany. Ms. Masterson is the Chair Emeritus of the Bay Bio Institute, a c and part of BayBio, which promotes science education, workforce development and best practices as well as entrepreneurs in the bioeconomy. Ms. Masterson began her business career at Ames Company, a division of Bayer, and spent eight years at Millipore Corporation in sales and sales management. Ms. Masterson has years of experience in the life science industry. She received her Masters in Biological Sciences from George Washington University, and continued Ph.D. work at the University of Florida.
  • John Bernard Payne / Independent Director
    • Mr. Payne was appointed to serve as a director of the Company in July, . He is currently President and CEO of Veterinary Specialists of North America, LLC. which owns and operates specialty and general practice veterinary hospitals in NJ, NY and PA. He also is the founder of Pet Health Innovations, LLC, an animal health consulting firm, having served as CEO since January, . He is the chairman of the board at American Humane Association, and he serves as a director of both Nerved Bio pharma plc and Great Expressions Dental Centers. He previously served as the President and CEO of Benfield Pet Hospitals from to the nation s largest private veterinary practice with more than fullservice hospitals, operating in the United States. In addition, he served as a member from to of the Mars Global Pet Care leadership team based in Brussels, representing over billion in the pet industry segment. Prior to Benfield and Mars, Mr. Payne served as President of Bayer Healthcare s North American Animal Health Division from to , part of the billion diversified international conglomerate.
  • Robert Rondeau / Independent Director

Current Share Structure

  • Market Cap: $16,590,537 - 03/16/2018
  • Authorized: 450,000,000 - 11/14/2016
  • Issue and Outstanding: 141,196,061 - 02/13/2018
  • Float: 98,311,588 - 12/31/2016

 


Recent Filings from (OTC: ZIVO)

Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: May, 15 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 30 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 27 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 25 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 25 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 23 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 12 2018
Amendment to a previously filed Form 3
Filing Type: 3/AFiling Source: edgar
Filing Date: February, 09 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (OTC: ZIVO)

Daily Technical Chart for (OTC: ZIVO)


Stay tuned for daily updates and more on (OTC: ZIVO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ZIVO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZIVO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ZIVO and does not buy, sell, or trade any shares of ZIVO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/